Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business

Impact · against what's priced in

Clarivate's divestiture of its Life Sciences & Healthcare unit is a catalyst for value unlock through debt reduction and margin expansion. The sale at a premium multiple (10x EBITDA) improves the balance sheet and shifts the business toward a high-predictability, 92% recurring revenue model.

CLVT+0.60

No priced-in read yet

In context

The $600 million sale of a low-margin, high-capex unit reduces net leverage by 1.5x and expands free cash flow margins by over 300 basis points.

Read from the article alone

• CLVTNew
• intellectual propertyNew
• divestiture▲700%
• life sciences
• m and a
• healthcare
• cash flow